Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where I Ferrara is active.

Publication


Featured researches published by I Ferrara.


The Scientific World Journal | 2014

Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells

Francesco Orio; Giovanna Muscogiuri; Stefano Palomba; Bianca Serio; M Sessa; Valentina Giudice; I Ferrara; Libuse Tauchmanovà; Annamaria Colao

Early and late endocrine disorders are among the most common complications in survivors after hematopoietic allogeneic- (allo-) and autologous- (auto-) stem cell transplant (HSCT). This review summarizes main endocrine disorders reported in literature and observed in our center as consequence of auto- and allo-HSCT and outlines current options for their management. Gonadal impairment has been found early in approximately two-thirds of auto- and allo-HSCT patients: 90–99% of women and 60–90% of men. Dysfunctions of the hypothalamus-pituitary-growth hormone/insulin growth factor-I axis, hypothalamus-pituitary-thyroid axis, and hypothalamus-pituitary-adrenal axis were documented as later complicances, occurring in about 10, 30, and 40–50% of transplanted patients, respectively. Moreover, overt or subclinical thyroid complications (including persistent low-T3 syndrome, chronic thyroiditis, subclinical hypo- or hyperthyroidism, and thyroid carcinoma), gonadal failure, and adrenal insufficiency may persist many years after HSCT. Our analysis further provides evidence that main recognized risk factors for endocrine complications after HSCT are the underlying disease, previous pretransplant therapies, the age at HSCT, gender, total body irradiation, posttransplant derangement of immune system, and in the allogeneic setting, the presence of graft-versus-host disease requiring prolonged steroid treatment. Early identification of endocrine complications can greatly improve the quality of life of long-term survivors after HSCT.


International Journal of Surgery | 2014

Bone and soft tissue non-Hodgkin lymphoma of the maxillofacial area: Report of two cases, literature review and new therapeutic strategies

Antonio Cortese; Giuseppe Pantaleo; I Ferrara; Alessandro Vatrella; I. Cozzolino; Vincenzo Di Crescenzo; Massimo Amato

Primary mandibular non-Hodgkin lymphoma (NHL) and soft tissues NHL of the maxillofacial are extremely rare representing a minimal percentage of the head and neck tumors. Two cases of bone and soft tissue maxillofacial NHL are reported. Clinical, radiological and pathological features are described and the therapeutic procedures are discussed accordingly. Mandibular radiologic features have been carefully analyzed and discussed to achieve an early and accurate diagnosis avoiding improper dental therapies.


Open Medicine | 2016

Efficacy and safety of splenectomy in adult autoimmune hemolytic anemia

Valentina Giudice; Rosa Rosamilio; I Ferrara; Elisa Seneca; Bianca Serio

Abstract Autoimmune hemolytic anemia (AIHA) is a rare hematologic disease, primarily affecting adults or children with immunodeficiency disease. First-line therapy consists of long course of steroids administration, with an early complete response rate (CRr) of 75-80%, but up to 20-30% of patients requires a second-line therapy. Rituximab is the first choice in refractory old AIHA patients, because of its safety and efficacy (early CRr at 80-90% and at 68% at 2-3 years). For this reason, splenectomy is even less chosen as second-line therapy in elderly, even though laparoscopic technique decreased complication and mortality rates. However, splenectomy can be still considered a good therapeutic option with a CRr of 81% at 35.6 months in patients older than 60 year-old, when rituximab administration cannot be performed.


Translational Medicine @ UniSa | 2016

In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells

Giudice; Patrizia Ricci; Luigi Marino; M Rocco; G Villani; M Langella; L Manente; Elisa Seneca; I Ferrara; L Pezzullo; B Serio


Haematologica | 2013

Continuous alternate-day low dose lenalidomide in combination with low dose prednisone as frontline treatment for octogenarian newly diagnosed multiple myeloma patients

L Pezzullo; R Fontana; B Serio; I Ferrara; M Sessa; G Villani; M Rocco; Rosa Rosamilio; C De Luca


Blood | 2016

The Role of B Regulatory Cells in the Immunological Escape of Tumor Cells in Hodgkin Lymphoma

Valentina Giudice; M Rocco; G Villani; Rosa Rosamilio; L Pezzullo; Bianca Serio; I Ferrara


Haematologica | 2015

High incidence of cytomegalovirus reactivation in patients with lymphoma treated with bendamustine

L Pezzullo; Giudice; I Ferrara; Silvana Annunziata; B Serio; R Fontana


TRANSLATIONAL MEDICINE @ UNISA | 2014

Lenalidomide-Mediated NK Cells Expansion In Elderly Multiple Myeloma Patients

M Sessa; Giudice; B. Esposito; L Pezzullo; B Serio; I Ferrara; Carmine Selleri


Bone Marrow Transplantation | 2014

Continuous maintenance therapy with alternate-day low dose lenalidomide in multiple myeloma patients after autologous stem cell transplantation increases the number of circulating natural killer cells

L Pezzullo; R Fontana; B Serio; Silvana Annunziata; M Sessa; I Ferrara; Valentina Giudice; B. Esposito; G Villani; M Rocco


Bone Marrow Transplantation | 2014

Daily low-dose valgancyclovir is safe and effective CMV-reactivation prophylaxis in HLA-identical sibling hematopoietic stem cell transplantation

Valentina Giudice; B Serio; M Sessa; L Pezzullo; R Fontana; Silvana Annunziata; I Ferrara; M Rocco

Collaboration


Dive into the I Ferrara's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

M Rocco

University of Salerno

View shared research outputs
Top Co-Authors

Avatar

M Sessa

University of Salerno

View shared research outputs
Top Co-Authors

Avatar

B Serio

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

R Fontana

University of Salerno

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G Villani

University of Salerno

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge